Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized placebo-controlled study of CSJ148 in pregnant women with primary HCMV infection
MOH_2022-04-24_002048Phase 2Completed
- Sponsor
- Novartis
- Start
- Dec 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, triple-blind trial in congenital cytomegalovirus infection (cCMV) comparing CSJ148 with Placebo (2 arms). Started Dec 2018; status: completed.
02
Drugs
CSJ148
03
Conditions
congenital cytomegalovirus infection (cCMV)
Beyond the preview
Go deeper on MOH_2022-04-24_002048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-04-24_002048.